Ascentage Pharma

Executive Summary

Ascentage Pharma is a global biopharmaceutical company uniquely focused on developing first- and best-in-class small molecule therapies targeting apoptosis pathways for cancer and other diseases. Founded in 2009 and headquartered in Rockville, Maryland, the company is the only developer with active clinical programs addressing all three known classes of key apoptosis regulators (BCL-2, IAP, and MDM2/p53). Its proprietary drug discovery platform enables targeting of challenging mechanisms, positioning it as a leader in programmed cell death therapeutics. Ascentage’s lead asset, lisaftoclax (APG-2575), a selective BCL-2 inhibitor, has shown promise in hematologic malignancies, including chronic lymphocytic leukemia (CLL), and is advancing in pivotal trials. The company also has a pipeline of apoptosis-based candidates, such as APG-115 (MDM2 inhibitor) and APG-1387 (IAP inhibitor), targeting solid tumors and other indications. With a strong scientific foundation and a focus on high-unmet-need areas, Ascentage Pharma represents a compelling opportunity in the precision oncology space, though it remains in a development stage without approved products to date.

Upcoming Catalysts (preview)

• Q3 2026Lisaftoclax (APG-2575) Phase 3 pivotal data readout in CLL80% success
• Q4 2026Potential NDA submission for lisaftoclax in relapsed/refractory CLL70% success
• TBDPartnership or licensing deal for APG-115 or APG-1387 in Asia60% success